DRISCOLL FREDERICK W 4

What Happened

• Frederick W. Driscoll, a director of Cellectar Biosciences, was granted a derivative award for 25,000 shares on July 7, 2026. The award was reported on an SEC Form 4 filed July 8, 2026. The reported acquisition price is $0.00, meaning Driscoll did not pay cash for the award at grant.

Key Details

• Transaction type: Award/Grant (derivative) — code A on Form 4
• Transaction date: July 7, 2026; Form 4 filed July 8, 2026 (timely filing)
• Number of shares/units granted: 25,000
• Price: $0.00 at grant (no immediate cash outlay)
• Vesting: The award "shall vest in full on July 7, 2027," contingent on continued service (per footnote)
• Shares owned after transaction: Not specified in the excerpt provided
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing

Context

• This was a grant of a derivative award (likely stock options or restricted stock units) that does not result in immediate market shares; the award vests one year from grant if Driscoll remains in service. Such grants are common for directors and are compensation-related rather than open-market purchases or sales.